Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts

Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse... Decitabine (DAC), an inhibitor of DNA methyltransferase, demonstrates antitumor activities in various types of cancer. However, its therapeutic potential for cholangiocarcinoma (CCA), one of the most aggressive gastrointestinal malignancies, remains to be explored. The present study investigated the antiproliferative effects of DAC on CCA cells in vitro and in vivo. Human CCA cell lines, TFK‑1 and QBC939, were used as models to investigate DAC on the cell growth and proliferation of CCA. Cell proliferation was evaluated by Cell Counting Kit‑8 assay combined with clonogenic survival assay. Flow cytometry, Hoechst 33342/propidium iodide staining and green fluorescent protein‑tagged MAP‑LC3 detection were applied to determine cell cycle progression, apoptosis and autophagy. Nude mice with TFK‑1 xenografts were evaluated for tumor growth following DAC treatment. DAC was observed to significantly suppress the proliferation of cultured TFK‑1 and QBC939 cells, accompanied with enhanced apoptosis, autophagy and cell cycle arrest at G2/M phase. In TFK‑1 mouse xenografts, DAC retarded the tumor growth and increased the survival of CCA tumor‑bearing mice. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology Letters Spandidos Publications

Decitabine inhibits the cell growth of cholangiocarcinoma in cultured cell lines and mouse xenografts

Download PDF
6 pages

Loading next page...
 
/lp/spandidos-publications/decitabine-inhibits-the-cell-growth-of-cholangiocarcinoma-in-cultured-snD6bTg2AY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Spandidos Publications
Copyright
Copyright © Spandidos Publications
ISSN
1792-1074
eISSN
1792-1082
DOI
10.3892/ol.2014.2499
Publisher site
See Article on Publisher Site

Abstract

Decitabine (DAC), an inhibitor of DNA methyltransferase, demonstrates antitumor activities in various types of cancer. However, its therapeutic potential for cholangiocarcinoma (CCA), one of the most aggressive gastrointestinal malignancies, remains to be explored. The present study investigated the antiproliferative effects of DAC on CCA cells in vitro and in vivo. Human CCA cell lines, TFK‑1 and QBC939, were used as models to investigate DAC on the cell growth and proliferation of CCA. Cell proliferation was evaluated by Cell Counting Kit‑8 assay combined with clonogenic survival assay. Flow cytometry, Hoechst 33342/propidium iodide staining and green fluorescent protein‑tagged MAP‑LC3 detection were applied to determine cell cycle progression, apoptosis and autophagy. Nude mice with TFK‑1 xenografts were evaluated for tumor growth following DAC treatment. DAC was observed to significantly suppress the proliferation of cultured TFK‑1 and QBC939 cells, accompanied with enhanced apoptosis, autophagy and cell cycle arrest at G2/M phase. In TFK‑1 mouse xenografts, DAC retarded the tumor growth and increased the survival of CCA tumor‑bearing mice.

Journal

Oncology Letters – Spandidos Publications

Published: Nov 1, 2014

References

  • Biliary tract cancers
    de Groen
  • The epidemiology of cholangiocarcinoma
    Shaib
  • Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?
    Khan
  • Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections
    Nagino
  • Chemoprevention and screening in primary sclerosing cholangitis
    Kitiyakara
  • Current consensus on the management of primary sclerosing cholangitis
    Wiencke
  • EASL Recognition Awardee 2009: Prof
    Beuers
  • Diagnosis and management of primary sclerosing cholangitis
    Chapman
  • One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality
    Sano
  • Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study
    Shaib
  • Inflammation and carcinogenesis of the biliary tract: update on endoscopic treatment
    Kozarek
  • Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment
    Blechacz
  • Cholangiocarcinoma: a compact review of the literature
    Ustundag
  • Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma
    Ramacciato
  • Intrahepatic cholangiocarcinoma: prognostic factors after liver resection
    Nuzzo
  • Diagnosis and treatment of cholangiocarcinoma
    Anderson
  • Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer
    Cheung
  • Structure and function of mammalian DNA methyltransferases
    Jurkowska
  • Decitabine - bedside to bench
    Oki
  • DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Griffiths
  • Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation
    Gravina
  • Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine
    Damaraju
  • Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo
    Yang
  • Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy
    Schnekenburger
  • Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy
    Chen
  • DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo
    Yi